NDRA

ENDRA Life Sciences Inc. (NDRA) - Q2 2024 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended June 30, 2024. ENDRA Life Sciences Inc. is a medical technology company developing Thermo-Acoustic Enhanced Ultrasound (TAEUS) technology for non-invasive tissue characterization, specifically targeting the diagnosis of nonalcoholic fatty liver disease (NAFLD). The company holds CE mark approval for its TAEUS FLIP system in the EU but is currently pursuing FDA de novo clearance in the United States. As of the reporting date, the company has generated no commercial revenue.

Key Financial Metrics

Expense Breakdown (YTD 2024): Research and Development ($1.76M), General and Administrative ($2.85M), Sales and Marketing ($0.40M).

Material Changes vs. Prior Period

• Capital Raise: In June 2024, the company completed a registered offering raising net proceeds of approximately $7.34 million. This included the sale of common stock and pre-funded warrants, significantly increasing cash reserves from $2.83M at year-end 2023 to $6.40M.
• Share Count Expansion: Outstanding common shares increased from ~10.4 million (Dec 31, 2023) to 72.4 million (June 30, 2024) due to the offering and warrant exercises.
• Expense Reduction: Total operating expenses decreased by approximately 15% year-over-year (YTD), driven primarily by a 37% reduction in R&D costs as the company shifted focus from initial product development to clinical trials and commercialization.
• Debt Elimination: The company fully repaid its Canadian Emergency Business Account loan ($28,484) during the first half of 2024.
• Inventory Reserve: The company established a 5% inventory shrinkage reserve ($142,733) due to potential damage and longer sales timeframes.

Outlook, Risks, and Management Commentary

• Going Concern: Management explicitly states that the company's ability to continue as a going concern is dependent on obtaining adequate capital. With an accumulated deficit of nearly $97 million and no revenue, the company requires additional financing to fund operations for the next 12 months.
• Regulatory Path: The company anticipates completing necessary clinical studies for its NAFLD application by Q4 2024 or Q1 2025, with a new de novo submission to the FDA expected in the first half of 2025.
• Leadership Changes: Subsequent to the period end, the company announced the resignation of CEO Francois Michelon and CFO Irina Pestrikova. Alexander Tokman was appointed Acting CEO and Chairman, and Richard Jacroux was appointed CFO.
• Corporate Actions: Shareholders approved a 1-for-50 reverse stock split and an increase in authorized shares to 1 billion. The Series A and B warrants issued in the June offering were approved by shareholders in August 2024.
• Internal Controls: The company identified a material weakness in internal controls over financial reporting due to insufficient personnel resources to segregate duties.

Investor Verification Checklist

• Cash Runway: Verify if the $6.4M cash balance is sufficient to fund operations through the anticipated FDA submission in H1 2025, given the burn rate of ~$4.2M in operating cash flow for the first six months.
• Dilution Impact: Assess the impact of the 1-for-50 reverse stock split and the significant increase in share count (to 72.4M) on future liquidity and market capitalization.
• Regulatory Timeline: Monitor the progress of the FDA de novo submission and the completion of clinical studies, as delays could necessitate further capital raises.
• Leadership Stability: Evaluate the transition plan for the new CEO and CFO and the potential impact on strategic execution.
• Warrant Terms: Review the terms of the newly issued Series A and B warrants, including exercise prices ($0.22) and potential dilution upon exercise.